Get the Stockscreener App
1,149.36
0.88%
-10.24
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,149.36, with a volume of 2.16M.
It is down -0.88% in the last 24 hours and up +3.02% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,159.60
Open:
$1150.61
24h Volume:
2.16M
Relative Volume:
0.77
Market Cap:
$1.02T
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
41.37
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
-2.15%
1M Performance:
+3.02%
6M Performance:
+14.53%
1Y Performance:
+54.71%
1-Day Range:
$1,138.31
$1,158.44
1-Week Range:
$1,137.50
$1,188.33
52-Week Range:
$712.05
$1,292.65
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,149.36 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
275.23 | 644.33B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
256.46 | 462.68B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
150.33 | 367.58B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
159.99 | 296.97B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider - GlobeNewswire Inc.
Eli Lilly expands US pharmaceutical manufacturing with Over US$50bn investment - Scientist Live
Eli Lilly’s $100B incretin opportunity: Is more upside coming? - Investing.com
Prediction: Here's What a $5,000 Investment in Eli Lilly Could Look Like in 5 Years - The Motley Fool
Will Eli Lilly Split Its Stock? Here's What History Says Will Happen If It Does. - The Motley Fool
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - GlobeNewswire Inc.
Lilly looks beyond obesity with $2.88B autoimmune buyout - thestreet.com
The Oral GLP-1 Tracker: Novo's Wegovy pill, Lilly's Foundayo grow scripts - fiercepharma.com
DRUGS AND BIOLOGICS—5th Cir.: Fifth Circuit upholds FDA's removal of tirzepatide from drug shortage list, rejecting compounders' APA challenges - VitalLaw.com
Eli Lilly and Company $LLY Shares Bought by BNP Paribas - InsuranceNewsNet
Eli Lilly Just Announced a Major Acquisition. Here's What It Means. - The Motley Fool
Eli Lilly’s Foundayo Launches in UK Amid Counterfeit Risks - healthcare-digital.com
Lilly to acquire Merida Biosciences for up to $2.875bn - Manufacturing Chemist
Lilly’s Merida Deal Shows the GLP-1 King Is Already Thinking Beyond Obesity - MarketBeat
JPMorgan reiterates Eli Lilly stock rating on incretin growth - Investing.com
This New Zepbound Study Could Be Great News for Eli Lilly Investors - The Motley Fool
Eli Lilly to Buy Immunology Biotech Merida Biosciences in $2.9B Deal - Yahoo Finance
Lilly to acquire biotechnology company for $2.8B - dailyjournal.net
Lilly’s dealmaking spreads the wealth among a broad set of biotech venture investors - Endpoints News
BMO reiterates Eli Lilly stock Outperform on Merida acquisition - Investing.com
Merida Biosciences Acquisition by Eli Lilly for Up to $2.875 Bil - GuruFocus
Eli Lilly to buy Merida Biosciences for up to $2.88B, expanding immunology pipeline - Yahoo! Finance Canada
Lilly snags another Massachusetts biotech as local headcount surges past 1,400 - The Business Journals
Eli Lilly to Acquire Merida Biosciences for Up to $2.875 Billion - citybiz
Eli Lilly to Buy Merida Biosciences for Up to $2.875 Billion - WSJ
Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases - investor.lilly.com
FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes - investor.lilly.com
Eli Lilly and Co Stock (LLY) Opened Down by 3.57% on Aug 26: Facts Behind the Movement - TradingKey
Eli Lilly: Shaking Off Competition From The Dethroned Novo Nordisk (NYSE:LLY) - Seeking Alpha
Novo Nordisk: The Pill That Could Close The Gap With Lilly (NYSE:NVO) - Seeking Alpha
Here’s How Much You Would Have Made Owning Eli Lilly Stock In The Last 5 Years - Benzinga
Eli Lilly and Company (NYSE:LLY) Shares Up 1%Here's What Happened - MarketBeat
Bristol-Myers Squibb (BMY) Bets $2.3 Billion on Texas While Eli Lilly (LLY) Wins in the UK - Yahoo Finance
Eli Lilly will replace lost insulin after Indiana storms - nwitimes.com
Amplitude Therapeutics and Lilly Partner to Advance Trans-Amplifying RNA Vaccine Platform for Infectious Disease - BioPharm International
Stock Split Watch: Is Eli Lilly (LLY) Stock Next? - The Motley Fool
Lilly to work with Boston-based firm to develop RNA vaccine platform - dailyjournal.net
Roundup: Amplitude Therapeutics, Chai Discovery Enter Collaborations with Eli Lilly, Bristol Myers Squibb - Pharmaceutical Executive
Eli Lilly (NYSE:LLY) Shows Strong Growth and a Compelling Technical Setup - ChartMill
How cost and perception could reshape the GLP-1 market - BioPharma Dive
Eli Lilly and Company $LLY Shares Acquired by Kelleher Financial Advisors - MarketBeat
Private Advisory Group LLC Purchases 2,056 Shares of Eli Lilly and Company $LLY - MarketBeat
M3 Wealth Management LLC Purchases Shares of 2,836 Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Stock Holdings Decreased by SMART Wealth LLC - MarketBeat
Russell Investments Group Ltd. Has $942.43 Million Stake in Eli Lilly and Company $LLY - MarketBeat
Focus Partners Advisor Solutions LLC Has $16.78 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
3,643 Shares in Eli Lilly and Company $LLY Purchased by Bellars Harris Wealth Management LLC - MarketBeat
ABN AMRO Bank N.V. Reduces Stock Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company (NYSE:LLY) Stock Price Down 2.6%Time to Sell? - MarketBeat
There’s a Black Market for Eli Lilly’s Unapproved GLP-1 Drug. Here’s Why That’s Bullish - The Motley Fool
Eli Lilly reveals plans for Lehigh Valley construction to avoid traffic problems. Here are the details. - The Morning Call
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):